Journal Article Ahead of print
PubMed: 42037015 DOI: 10.1002/mdc3.70656
Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice.
Mov Disord Clin Pract
Authors: Frank Jagusch, Elena Redl, Christoph Theyer, Atbin Djamshidian, Alessandra Fanciulli, Werner Poewe, Philipp Mahlknecht, Beatrice Heim, Klaus Seppi, Florian Krismer
Affiliations
- Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
Abstract
BACKGROUND
Reduced cardiac uptake on 123Iodine-metaiodobenzylguanidine (MIBG) scintigraphy is a valuable tool for differentiating neurodegenerative parkinsonism but interpretation can be difficult due to comorbidities and drug-tracer interactions.
OBJECTIVES
This study investigated factors limiting the clinical applicability of MIBG scintigraphy in everyday clinical practice.
METHODS
Patient records (2021-2022) were retrospectively reviewed, independent of whether MIBG scintigraphy was performed, for comorbidities and concomitant medication confounding its interpretation.
RESULTS
Six hundred ninety five patients (640 Parkinson's disease, 22 multiple system atrophy, 33 progressive supranuclear palsy) were included. Factors potentially influencing cardiac MIBG binding were present in 55.3% with 18.1% exhibiting multiple factors. Medications with known drug-tracer interactions were found in 46.9% and comorbidities associated with reduced cardiac MIBG uptake in 20.9%.
CONCLUSIONS
The clinical utility of MIBG scintigraphy is frequently restricted by medications and comorbidities highlighting the need of careful planning in clinical practice.
MeSH
Comorbidity, Supranuclear Palsy, Progressive, Multiple System Atrophy, Pharmaceutical Preparations, Parkinsonian Disorders, 3-Iodobenzylguanidine, Radionuclide Imaging